ReviewViruses2022
Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Influence of vaccination against infectious diseases on the carbon footprint of fattening pigs: a systematic review.Frontiers in veterinary science · 2024Pooled it
- Hijacking of host PCNA by circovirus replication-associated protein to recruit POLD1 drives viral DNA replication and is inhibited by R428.PLoS pathogens · 2026Article
- The Prevalence and Genetic Diversity of Porcine Circoviruses (PCVs) in Eastern China During 2010-2016 and 2023-2024.Veterinary sciences · 2026Article
- Preparation of Monoclonal Antibodies Against Porcine Circovirus Type 2 Capsid Protein and Development of a Blocking ELISA for Detection of the Antibody Against the Virus.Veterinary sciences · 2026Article
- ORF3 protein of porcine circovirus type 2 induced RIPK3 phosphorylation-driven autophagy to promote viral replication.Scientific reports · 2026Article
- Epidemiological investigation of PCV2 and PCV3 in three provinces of Northeast China in 2025.BMC veterinary research · 2026Article
- Preparation and Immune Protective Efficacy Evaluation of PCV2d Cap-COS Bioconjugate Candidate Vaccine.ACS omega · 2026Article
- Development of Magnetic Particle-Based Chemiluminescence Immunoassays for Detecting PCV2 VLP- and Rep-Specific Antibodies and Their Combined Use for Immune Evaluation and Replication-Associated Exposure Assessment.Transboundary and emerging diseases · 2026Article
- A porcine circovirus type 2d-based virus-like particle subunit vaccine effectively protects pigs against homologous challenge.Frontiers in microbiology · 2026Article
- Identification of novel CRESS-DNA viruses in the human vaginal microbiome.Frontiers in microbiology · 2026Article
- Virus-like Particles Carrying a Porcine Circovirus Type 2b Peptide Induce an Antibody Response and Reduce Viral Load in Immunized Pigs.Vaccines · 2025Article
- The C1QTNF6-MX2 Antiviral Axis Inhibits Porcine Circovirus Type 2 Replication in Porcine Macrophages.Veterinary sciences · 2025Article
- Current Knowledge on the Diagnostic Methods, Epidemiological Characteristics and Antiviral Strategies of Chicken Anemia Virus.Veterinary sciences · 2025Review
- Knowledge gaps in research and control of porcine circovirus 2 (PCV2) infections.BMC veterinary research · 2025Review
- Efficacy and Safety Evaluation of a Ready-to-Use Bivalent Porcine Circovirus Type 2 andVaccines · 2025Article
- Design of a Golden Gate Cloning Plasmid for the Generation of a Chimeric Virus-Like Particle-Based Subunit Vaccine Against Porcine Circovirus Type 2.Molecular biotechnology · 2025Article
- Efficacy of a new ready-to-use PCV2 andVeterinarni medicina · 2025Article
- Efficacy of a Novel PCV2d andVaccines · 2025Article
- Article
- Speculative Review on the Feasibility of Porcine Circovirus 2 Elimination.Animals : an open access journal from MDPI · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine circovirus type 2 (PCV2) infection can lead to porcine circovirus-associated disease (PCVAD), causing great economic losses to the global swine industry. Conventional vaccination programs are a major measure in the prevention and control of this disease. Currently, there are 5 commercially available PCV2 vaccines in the international market and 10 kinds commercially available PCV2 vaccines in the Chinese market that confer good efficacy against this virus by alleviating clinicopathological manifestations and enhancing growth performance in pigs. In addition, diverse experimental PCV2 vaccines with protective efficiency have been developed, including attenuated chimeric, nucleic acid, subunit, multivalent, and viral-vectored vaccines. These experimental vaccines have been shown to be relatively effective in improving the efficiency of pig production and simplifying prevention procedures. Adjuvants can be used to promote vaccines with higher protective immunity. Herein, we review the application of multiple commercial vaccines over the years and research advances in experimental vaccines, which provide the possibility for the development of superior vaccines to successfully prevent and control PCV2 infection in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.